Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival.

Petricoin EF 3rd, Espina V, Araujo RP, Midura B, Yeung C, Wan X, Eichler GS, Johann DJ Jr, Qualman S, Tsokos M, Krishnan K, Helman LJ, Liotta LA.

Cancer Res. 2007 Apr 1;67(7):3431-40.

3.

Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.

Yamada Y, Kohashi K, Fushimi F, Takahashi Y, Setsu N, Endo M, Yamamoto H, Tokunaga S, Iwamoto Y, Oda Y.

Cancer. 2014 Mar 15;120(6):864-76. doi: 10.1002/cncr.28506. Epub 2013 Dec 18.

5.

Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes.

Tremblay F, Gagnon A, Veilleux A, Sorisky A, Marette A.

Endocrinology. 2005 Mar;146(3):1328-37. Epub 2004 Dec 2.

PMID:
15576463
6.
7.
8.

Mammalian target of rapamycin is activated in association with myometrial proliferation during pregnancy.

Jaffer S, Shynlova O, Lye S.

Endocrinology. 2009 Oct;150(10):4672-80. doi: 10.1210/en.2009-0419. Epub 2009 Jul 9.

PMID:
19589861
9.

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N.

Cancer Res. 2006 Feb 1;66(3):1500-8.

10.

Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.

Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D.

Clin Cancer Res. 2004 Oct 15;10(20):6779-88.

11.

A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.

Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.

BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.

12.

Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.

Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ.

Am J Pathol. 2006 Dec;169(6):2171-80.

13.

Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.

Nathan CO, Amirghahari N, Abreo F, Rong X, Caldito G, Jones ML, Zhou H, Smith M, Kimberly D, Glass J.

Clin Cancer Res. 2004 Sep 1;10(17):5820-7.

14.

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40.

Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH.

Nat Cell Biol. 2007 Mar;9(3):316-23. Epub 2007 Feb 4.

PMID:
17277771
15.

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

Wan X, Harkavy B, Shen N, Grohar P, Helman LJ.

Oncogene. 2007 Mar 22;26(13):1932-40. Epub 2006 Sep 25.

PMID:
17001314
16.

Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling.

Martin KA, Merenick BL, Ding M, Fetalvero KM, Rzucidlo EM, Kozul CD, Brown DJ, Chiu HY, Shyu M, Drapeau BL, Wagner RJ, Powell RJ.

J Biol Chem. 2007 Dec 7;282(49):36112-20. Epub 2007 Sep 30.

17.
19.

The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.

Follo MY, Mongiorgi S, Bosi C, Cappellini A, Finelli C, Chiarini F, Papa V, Libra M, Martinelli G, Cocco L, Martelli AM.

Cancer Res. 2007 May 1;67(9):4287-94.

20.

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.

Clin Cancer Res. 2004 Dec 1;10(23):8059-67.

Supplemental Content

Support Center